HK Stock Movement | Zai Lab (09688) Rises Over 4% in Early Trading as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China

Stock News

Dec 24

Zai Lab (09688) surged more than 4% in early trading, reaching HK$14.1 with a turnover of HK$59.19 million by the time of reporting. The uptick follows the company's announcement on December 23 that China's National Medical Products Administration (NMPA) has approved the new drug application for xanomeline-trospium chloride capsules (KAI JIE LE) for treating adult schizophrenia. This marks the first schizophrenia therapy with a novel mechanism of action approved in over 70 years, representing a fundamental breakthrough in treatment.

In November 2021, Zai Lab secured exclusive rights from Karuna Therapeutics to develop, manufacture, and commercialize xanomeline-trospium chloride capsules in Greater China for $187 million. The NMPA's approval was based on data from a Phase I pharmacokinetic study in China, a Phase III clinical trial (ZL-2701-001), and three global EMERGENT clinical studies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1189613078"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189613078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189613078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189613078","market":"hk","top_or_hot":-1,"title":"HK Stock Movement | Zai Lab (09688) Rises Over 4% in Early Trading as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China","media":"Stock News","content":"<p>Zai Lab (09688) surged more than 4% in early trading, reaching HK$14.1 with a turnover of HK$59.19 million by the time of reporting. The uptick follows the company's announcement on December 23 that China's National Medical Products Administration (NMPA) has approved the new drug application for xanomeline-trospium chloride capsules (KAI JIE LE) for treating adult schizophrenia. This marks the first schizophrenia therapy with a novel mechanism of action approved in over 70 years, representing a fundamental breakthrough in treatment.</p>\n<p>In November 2021, Zai Lab secured exclusive rights from Karuna Therapeutics to develop, manufacture, and commercialize xanomeline-trospium chloride capsules in Greater China for $187 million. The NMPA's approval was based on data from a Phase I pharmacokinetic study in China, a Phase III clinical trial (ZL-2701-001), and three global EMERGENT clinical studies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | Zai Lab (09688) Rises Over 4% in Early Trading as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | Zai Lab (09688) Rises Over 4% in Early Trading as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-24 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zai Lab (09688) surged more than 4% in early trading, reaching HK$14.1 with a turnover of HK$59.19 million by the time of reporting. The uptick follows the company's announcement on December 23 that China's National Medical Products Administration (NMPA) has approved the new drug application for xanomeline-trospium chloride capsules (KAI JIE LE) for treating adult schizophrenia. This marks the first schizophrenia therapy with a novel mechanism of action approved in over 70 years, representing a fundamental breakthrough in treatment.</p>\n<p>In November 2021, Zai Lab secured exclusive rights from Karuna Therapeutics to develop, manufacture, and commercialize xanomeline-trospium chloride capsules in Greater China for $187 million. The NMPA's approval was based on data from a Phase I pharmacokinetic study in China, a Phase III clinical trial (ZL-2701-001), and three global EMERGENT clinical studies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1189613078","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189613078","pubTimestamp":1766540845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zai Lab (09688) surged more than 4% in early trading, reaching HK$14.1 with a turnover of HK$59.19 million by the time of reporting. The uptick follows the company's announcement on December 23 that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK1574":"生物医药B类股","09688":"再鼎医药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK1588":"回港中概股","BK4548":"巴美列捷福持仓","ZLAB":"再鼎医药","BK4531":"中概回港概念","BK4588":"碎股","BK1161":"生物科技"},"translate_title":"港股动向|再鼎医药(09688)早盘涨超4%精神分裂症突破性药物凯捷乐获中国批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZLAB":1,"09688":1},"content_text":"Zai Lab (09688) surged more than 4% in early trading, reaching HK$14.1 with a turnover of HK$59.19 million by the time of reporting. The uptick follows the company's announcement on December 23 that China's National Medical Products Administration (NMPA) has approved the new drug application for xanomeline-trospium chloride capsules (KAI JIE LE) for treating adult schizophrenia. This marks the first schizophrenia therapy with a novel mechanism of action approved in over 70 years, representing a fundamental breakthrough in treatment.\nIn November 2021, Zai Lab secured exclusive rights from Karuna Therapeutics to develop, manufacture, and commercialize xanomeline-trospium chloride capsules in Greater China for $187 million. The NMPA's approval was based on data from a Phase I pharmacokinetic study in China, a Phase III clinical trial (ZL-2701-001), and three global EMERGENT clinical studies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}